AbbVie Inc. (ABBV): what the price assumes

In the published model solve dated 2026-Q2, anchored at $256.00, AbbVie Inc. (ABBV) is priced for +14.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/ABBV

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.5% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.3%); the inversion above states its own rate.

Per-Model Detail (n=7)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Two drugs launched to replace one now carry 43% of revenue between them, and the 10-K reports that "Net revenues for Skyrizi increased 50% in 2025 primarily driven by continued strong market share uptake as well as market growth across all indications" on a constant-currency basis.
• The old franchise is still unwinding underneath that, with the Q1 FY2026 10-Q reporting Humira net revenues down 40% in the March 2026 quarter on direct biosimilar competition, which is what a patent cliff looks like while it is happening.
• Second-quarter results land on July 31, 2026, and the number to watch is not the headline but whether immunology growth still covers the erosion without leaning on price.

Bull Case

Drug companies are hard to value for one structural reason: their revenue arrives with an expiry date printed on it. The FY2025 10-K states the mechanic without softening it, warning that "The expiration or loss of patent protection for a product typically is followed promptly by substitutes that may significantly reduce sales for that product in a short amount of time." Every large pharmaceutical business is therefore in one of three states, replacing a franchise it is about to lose, losing one it failed to replace, or briefly at rest between the two. The bull case here is that AbbVie is visibly in the first state and further through it than the market treats it as being.

Look at what replaced what. Humira, once the largest-selling drug in the industry, is down to 7% of revenue. Skyrizi is 29% and Rinvoq is 14%, so the two successors together carry more than six times the weight of the franchise they were built to succeed. The 10-K reports that "Net revenues for Skyrizi increased 50% in 2025 primarily driven by continued strong market share uptake as well as market growth across all indications" and that Rinvoq grew 39% over the same year, both on a constant-currency basis. Very few companies have executed a replacement of that size on that schedule. Most talk about it for years and then buy something.

The second-order point is that the replacement did not narrow the business. Neuroscience runs through Vraylar, Ubrelvy, Qulipta and the Parkinson's therapies; oncology through Imbruvica, Venclexta and Elahere; aesthetics through Botox and Juvederm; and eye care through a further set. No single product outside Skyrizi carries more than 14% of revenue. The Q1 FY2026 10-Q notes that "Net revenues for Botox Cosmetic increased 17% for the three months ended March 31, 2026" on pricing and stocking effects, which is a reminder that a consumer-paid aesthetics business behaves nothing like a reimbursed immunology one and does not fail at the same time.

The reported profit understates what the business generates, and the gap is mechanical rather than promotional. Free cash flow ran near $19.98B against trailing net income of $3.6B, and the FY2025 10-K names most of the difference in one line: "Amortization expense was $ 7.4 billion in 2025, $ 7.6 billion in 2024 and $ 7.9 billion in 2023 and was included in cost of products sold in the consolidated statements of earnings." That is the accounting cost of drugs bought rather than discovered, charged against profit while the cash went out years ago. A reader who anchors on the reported earnings line is reading the acquisition history, not the current business.

Cash of that size funds the only thing that matters in this industry, which is the next replacement cycle. Research spending is rising as a share of revenue, and the Q1 FY2026 10-Q attributes the increase to "increased funding to support all stages of the company's pipeline assets", with upfront charges on acquired programmes running at $703 million in the quarter against $246 million a year earlier. The scale of that reinvestment is what separates the survivors from the harvesters, and the cohort shows the difference: Bristol-Myers, a peer of similar heritage, grew revenue 1.8% last year and Pfizer 1.4%, while AbbVie's top line moved considerably faster. The companies that stop buying and building pipeline are the ones that end up in the second state.

Bear Case

The single variable with the most leverage over this thesis is not a molecule. It is what a government decides a molecule is worth. The FY2025 10-K states the exposure without hedging: "Political and budgetary pressures in the United States and in other countries may also heighten the scope and severity of pricing pressures on AbbVie's products for the foreseeable future." It also notes that such measures "could, among other things, accelerate revenue erosion prior to expiration of intellectual property protections". Read that second clause slowly. It says the pricing regime can shorten the effective patent life of a drug, which is the one asset a pharmaceutical business actually owns, and it can do so without a court, a competitor or a failed trial being involved.

That matters more here than at a diversified peer because of what the price already assumes. Roughly 33 times a year of operating income implies operating growth near 18.8% a year from here, and the multiple sits at the very top of its sector distribution, well past the upper quartile. Only about 42% of comparable fast growers have kept that pace going that long. Now put a pricing action on top of it. Growth of that order depends on volume expansion in immunology holding while nothing compresses the price per prescription, and the negotiation frameworks the filing describes are aimed squarely at products with exactly Skyrizi's profile: large, reimbursed, high revenue per patient.

The concentration cuts against the diversification argument. Skyrizi at 29% and Rinvoq at 14% mean that 43% of revenue depends on two immunology products with overlapping payers, overlapping prescribers and, in due course, overlapping exclusivity expiries. The company knows what that sequence looks like from the inside. The Q1 FY2026 10-Q records that "Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity". The successors are not exempt from that arithmetic; they are simply earlier in it.

The balance sheet has less give than the cash generation suggests. Net debt stands at $55.6B, roughly 3.8 times operating income, with interest covered about 5 times. That is serviceable while the immunology franchise compounds, and it is a genuine constraint if a pricing action lands during a year when a large pipeline payment is also due. The company keeps buying programmes to feed the next cycle, and those payments are not optional if the replacement engine is to keep running. Meanwhile the share count has barely moved, down about 0.1% a year over the four years to March 2026, so there is no buyback cushioning per-share results if revenue growth slows.

The honest counter is that AbbVie has navigated exactly this once already and did it well, which is why the bull case above is not a straw man. The distinction is what gets rewarded. Successfully replacing Humira is now in the price; every family of standard valuation method lands below where the shares trade, and the methods anchored on reported profit land at roughly a third of it. What a buyer is underwriting from here is not the replacement that already happened. It is a second one, executed under a pricing regime the company itself describes as tightening for the foreseeable future.

Valuation

Anything built on this company's reported profit line will mislead you, so it is worth clearing that out first. Trailing operating income of $14.5B on revenue of $62.8B is a 23.1% operating margin, and reported net income of $3.6B is a long way below both. The 10-K explains the largest single reason in one sentence: "Amortization expense was $ 7.4 billion in 2025, $ 7.6 billion in 2024 and $ 7.9 billion in 2023 and was included in cost of products sold in the consolidated statements of earnings." That is the charge for medicines the company bought rather than invented, and the cash for them left the building years ago.

With that in hand, the embedded assumption reads cleanly. At $259.26 in late July 2026, the shares change hands at roughly 33 times a year of operating income, which implies operating growth near 18.8% annually. The arithmetic behind it runs at a 7.6% cost of capital with 4% terminal growth, and it is unusually input-sensitive here: a single additional point of cost of capital moves that growth reading by roughly 9.1 points. Against the company's own record the rate is not extreme, and about 42% of comparable fast growers have managed to keep such a pace going that long. The demand is persistence, not heroics.

Where the methods land is the awkward part. No family of standard valuation method reaches today's quote. The approaches that capitalize reported profit land at about a third of it, peer multiples at roughly half, and the dividend-based frames in between. The one lens that gets close sits inside the cash-flow work, which projects free cash flow forward at 10% a year rather than starting from the amortized profit line, and it arrives near the current quote. The distance between those two readings is not a disagreement about the business. It is a disagreement about whether an acquired drug is a cost or an asset, and the answer determines almost everything.

Against the peer cohort the profile is distinctive rather than cheap. Gilead runs a 34.9% operating margin and, in the same cohort, Amgen 28.4%, both above AbbVie's reported figure, though both also carry far lighter acquisition amortization. Eli Lilly, the peer the market currently rewards most, grew revenue 47.4% year over year against Bristol-Myers at 1.8%, which is the spread that explains why sector multiples are useless as a single benchmark right now. The cohort is not one business trading at one price. It is four or five different stages of the replacement cycle wearing the same label.

The balance sheet is where the risk actually accumulates. Net debt of $55.6B works out to roughly 3.8 times operating income, with interest covered around 5 times, and the share count has been flat, moving about 0.1% a year over the four years to March 2026. Those are workable numbers while immunology compounds, and they leave less room than the cash generation implies, because the same cash has to fund the next round of acquired programmes. The bet is that the second replacement cycle is financed out of the first one's success.

Catalysts

Second-quarter results are scheduled for the morning of July 31, 2026, with the call at 8 a.m. Central. Going in, management has guided Q2 net revenues to about $16.7B and full-year 2026 net revenues to roughly $67.3B, an increase of $300 million on the prior figure, after first-quarter net revenues of $15.0B grew 12.4% with about 2.1 points of that from currency. The currency contribution is worth separating out, because a weaker dollar flatters a business that sells globally and reverses without warning.

The company also raised its full-year 2026 adjusted earnings guidance by $0.12, to a range of $14.08 to $14.28 per share. That is a company-defined measure that excludes intangible amortization and acquired research charges, so it is not comparable to the reported earnings figure discussed above; it is useful mainly as a statement of management's own confidence in the immunology ramp. The gap between the two conventions is the widest single number in this report, and readers should treat the guided figure as an operating statement rather than an accounting one.

Underneath the guidance sit two moving pieces the July print will start to settle. The first is whether Skyrizi and Rinvoq are still taking share at the pace the FY2025 filings describe, or whether growth is now coming from price and stocking rather than patients. The second is pipeline spending: acquired programme charges reached $703 million in the March quarter, up from $246 million a year earlier, and a repeat of that scale would say management sees the second replacement cycle as urgent rather than distant.

Peer Cohorts (Per Segment, With Filing Citations)

Pharmaceutical Products (reported)

• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: …end of regulatory exclusivity or the COM patent expiration for the respective products and PTR if granted. In situations where there is only regulatory exclusivity without patent protection, a competitor could seek regulatory approval by submitting its own clinical study data to obtain marketing approval prior to the…
• FY2025 10-K: …pharmaceutical products are generally enforceable in the EU and, as in the U.S., may be extended for up to five years to compensate for the patent term lost during the regulatory review process, provided that the extension cannot cause the patent to be in effect for more than 15 years from the date of drug approval.…
• PFE (Pfizer Inc.)
• FY2025 10-K: …of generic drugs, including from generic versions of competitors' branded products that lose their market exclusivity, is a major challenge for our branded products. Certain of our products have experienced significant generic competition over the last few years. We anticipate a significant reduction of revenue from…
• FY2025 10-K: ProductsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-12-31 0000078003 pfe:B7H4VFelmetatugVedotinMember us-gaap:InProcessResearchAndDevelopmentMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003 pfe:MedrolMember pfe:BrandMember pfe:BiopharmaSegmentMember 2024-01-01 2024-12-31 0000078003…
• LLY (ELI LILLY & Co)
• FY2025 10-K: …with other pharmaceutical companies. For additional information, see Item 8, "Financial Statements and Supplementary Data-Note 3: Collaborations and Other Arrangements." Competition Our products compete globally with many other pharmaceutical products in highly competitive markets. Important competitive factors…
• FY2025 10-K: U.S. continue to significantly impact the market for pharmaceuticals through negotiation of access, manufacturer price or rebate concessions and pharmacy reimbursement rates. Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory…
• NVS (Novartis AG)
• FY2025 20-F: …the Biologics Price Competition and Innovation Act (BPCIA). In the EU, patents may be challenged through oppositions in the EPO, or revocation actions before the Unified Patent Court, whereas national patents may be challenged in national courts or national patent offices. The outcomes of such challenges can be…
• FY2025 20-F: …a wide range of activities, including pricing, product characteristics, customer service, sales and marketing, and research and development. Like other companies selling patented pharmaceuticals, Novartis faces challenges from companies selling competing patented products as well as from companies selling generics…
• AZN (ASTRAZENECA PLC)
• FY2025 20-F: …management ​ opemalirsen ​ podocyte health ​ ​ ​ nephropathy ​ Respiratory & Immunology ​ ​ ​ ​ ​ ​ ​ atuliflapon ​ FLAP inhibitor ​ ​ ​ asthma ​ AZD1163 ​ anti-PAD2/4 bispecific antibody ​ ​ ​ rheumatoid arthritis ​ AZD4604 ​ inhaled JAK1 inhibitor ​ ​ ​ asthma ​ AZD6793 ​ IRAK4 inhibitor ​ ​ ​ COPD ​ AZD7798 ​…
• FY2025 20-F: …(subcutaneous) ​ Launched ​ Tezspire CROSSING ​ TSLP mAb ​ (PP) ​ eosinophilic esophagitis ​ H2 2026 ​ Tezspire EMBARK, JOURNEY ​ TSLP mAb ​ (PP) ​ chronic obstructive pulmonary disease ​ >2027 ​ Tezspire WAYPOINT ​ TSLP mAb ​ (PP) ​ nasal polyps ​ Launched ​ Rare Disease ​ ​ ​ ​ ​ ​ ​ ​ ​ Koselugo KOMET ​ MEK…
• GSK (GSK plc)
• FY2025 20-F: …property continued Pharmaceutical products and intellectual property Patent expiry dates 1 Products Compounds Indication(s) US EU Specialty Medicines and Intellectual Property HIV Apretude cabotegravir HIV prevention 2031 2026-2031 2031 2031 Cabenuva/Vocabria + Rekambys cabotegravir, rilpivirine HIV/AIDS 2031…
• FY2025 20-F: …obstructive pulmonary disease (COPD) Phase III Eosinophilic granulomatosis with polyangiitis (EGPA) Phase III Hypereosinophilic syndrome (HES) Phase III Nucala (mepolizumab) Anti-interleukin 5 (IL5) antibody Chronic obstructive pulmonary disease (COPD) Approved A: 1Q26 A: 2Q25 linerixibat Ileal bile acid transporter…
• AMGN (Amgen Inc.)
• FY2025 10-K: Act Tax Cuts and Jobs Act of 2017 340B Program Federal 340B Drug Pricing Program AI artificial intelligence Amended 2009 Plan Amended and Restated 2009 Equity Incentive Plan AOCI accumulated other comprehensive income (loss) AstraZeneca AstraZeneca plc ASU Accounting Standards Update ATMOS Amgen Technology and Medical…
• FY2025 10-K: Regulation GIPR glucose-dependent insulinotropic polypeptide receptor GLP-1 glucagon like peptide 1 HHS U.S. Department of Health and Human Services ii Term Description Horizon Horizon Therapeutics plc IGF-1R insulin-like growth factor-1 receptor IgG4-RD Immunoglobulin G4-related disease IND Investigational New Drug…
• GILD (GILEAD SCIENCES, INC.)
• FY2025 10-K: …quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. 18 We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers. New branded or generic…
• FY2025 10-K: …activity to drive innovation and growth of our business. We extensively outsource our clinical trial activities and usually perform only a small portion of start-up activities in-house. We rely on third-party contract research organizations to perform most of our clinical studies, including document preparation, site…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.